AbbVie Inc., Viatris Inc., and Pfizer Inc. dominated the Germany Post-Traumatic Stress Disorder (PTSD) Market in 2022

Germany Post-Traumatic Stress Disorder (PTSD) Market is expected to grow with a CAGR of 4.4% in the forecast period of 2023 to 2030. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/germany-post-traumatic-stress-disorder-market

The Germany post-traumatic stress disorder (PTSD) market is a highly consolidated market, which includes a specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenarios.

Some of the major players dealing in the Germany Post-Traumatic Stress Disorder (PTSD) Market are introducing a wide range of products along with adopting strategic initiatives such as acquisitions, agreements, business expansions, and awards and recognitions into the market. These help companies maximize sales with an enhanced product portfolio.

For instance,

• In March 2022, AbbVie and Gedeon Richter Plc. (Richter) announced a new co-development and license agreement to research, develop, and commercialize novel dopamine receptor modulators for potentially treating neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and included several new chemical entities selected for development. AbbVie and Richter have collaborated for 15 years on Central Nervous System (CNS) projects, including globally launched products such as cariprazine (VRAYLAR/REAGILA). This collaboration helps the company expand its business and find new and innovative solutions and discoveries regarding neurological disorders.

AbbVie Inc. is the dominating player in the Germany Post-Traumatic Stress Disorder (PTSD) Market. The other key players existing in the market are Viatris Inc, Pfizer Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Aurobindo Pharma., AstraZeneca, Cipla Inc., Lupin, Accord Healthcare GmbH, Dr. Reddy’s Laboratories Ltd., Zydus Pharmaceuticals, Inc., GlaxoSmithKline Group of Companies., Teva Pharmaceutical Industries Ltd., Alkermes. and Novartis AG. among others.

AbbVie Inc.

AbbVie Inc. was founded in the year 2013 and is headquartered in Illnois, U.S. The company is a biopharmaceutical company engaged in new approaches to addressing today’s health issues, from life-threatening illnesses to chronic conditions. It has several product categories, including Immunology, Oncology, Aesthetics, Neuroscience, Eye care products, Women’s health products, Virology, Other Specialty Areas, and Gastroenterology, of which Neuroscience is the market-focused category.

For instance,

• In October 2021, AbbVie's announced the Cariprazine (VRAYLAR) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder or Post-Traumatic Stress Disorder (PTSD). Cariprazine showed a statistically significant change from baseline to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo. This helps the company to increase its R&D activities in the different segments of the disease areas.

It has a wide presence across North America, the Middle East and Africa, South America, Europe and Asia-Pacific. It has various subsidiaries that include Allergan, AbbVie GK, AbbVie Ireland unlimited company, Allergan Finance, Zeltiq Anesthetics, Stemcentrx, and AbbVie SAS, among others.

Viatris Inc.

Viatris Inc. was founded in the year 2020 and is headquartered in Canonsburg, Pennsylvania, United States. The company is engaged in producing and manufacturing a wide range of therapeutic products and the quality of medication. It has product categories Therapeutic Areas, Brands, generics, Biosimilars, Over counter, and API, in which Brands is the market-focused category.

The company has a wide presence across North America, Europe, South America, Asia-Pacific, and Middle East, and Africa.

Pfizer Inc.

Pfizer Inc. was founded in the year 1848 and is headquartered in New York, U.S. The company focuses on delivering breakthroughs that change patients' lives and translates advanced science and technologies into therapies. It has several product categories, including Primary care, Specialty care, and Oncology, in which Specialty care is the market-focused category.

For instance,

• In February 2021, U.S. Food and Drug Administration (FDA) approved Panzyga (Immune Globulin Intravenous [Human] – ifas 10 percent Liquid Preparation) as a treatment for adults with a neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP) is one example of how we're helping to transform the care of patients living with rare diseases.

The company has a presence across North America, Europe, Asia Pacific, South America, and Middle East & Africa.